Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

The AES Corporation (NYSE: AES) ("AES" or the "Company") announced that the previously announced tender offer to purchase (the "Tender Offer") for cash, subject to certain terms and conditions ...

BIP-UN.TO Brookfield Infrastructure Partners L.P.

Get notified when new properties matching your search criteria are listed on Allhomes ...